4DMedical Ltd Surges on Strong Performance and Key Announcements
4DMedical Ltd (ASX: 4DX) has captured the attention of investors this week after a strong start to the trading session. The stock is currently up 2.56% at $5.99, having previously reached an intraday high of $6.38. Despite a slight pullback due to broader market softness, with the S&P/ASX 200 Index (ASX: XJO) down 0.1% to 8,935 points, the overall trend for 4DMedical remains robust. The shares have risen approximately 50% in 2026 and an impressive 2,000% over the past year.
Major Updates Released Simultaneously
The company recently announced several key developments across commercial, regulatory, and market inclusion areas. These updates highlight the company’s growing influence in the healthcare sector.
Partnership with GlaxoSmithKline
One of the most significant announcements was a contract with GlaxoSmithKline, a global pharmaceutical and healthcare company based in the UK. The agreement focuses on supporting pulmonary drug development using 4DMedical’s imaging technology. GlaxoSmithKline is one of the largest drugmakers globally, known for its work in vaccines, specialty medicines, and consumer health products.
The one-year agreement will see 4DMedical provide lung imaging biomarkers across clinical trials. However, the financial terms of the deal were not disclosed.
Regulatory Clearances in the UK and Canada
In addition to the partnership, 4DMedical received regulatory clearance in the UK for its CT:VQ technology. This imaging solution uses CT scans to map how air and blood move through the lungs, producing detailed functional images that help clinicians detect and measure lung conditions without invasive tests. This follows CE Mark certification received in March, allowing for immediate clinical use.
The UK represents a significant market for diagnostic imaging, with millions of chest scans conducted annually. Additionally, the company also secured clearance for its coronary artery calcium analysis solution in Canada, further expanding its reach.
Reimbursement Progress in the United States
Another crucial update focused on progress in the U.S. A new reimbursement code has been established for AI-enabled coronary calcium analysis from CT scans. This code allows hospitals to claim around US$15.50 per study in the outpatient setting. This development creates a clear revenue pathway without requiring additional imaging or changes to workflow. Providers can integrate the analysis into existing scans, making it easier to adopt.
Reimbursement is often a critical step in moving imaging technologies into routine clinical use, and this development positions 4DMedical well for future growth.
ASX 200 Inclusion Boosts Visibility
4DMedical has also been added to the S&P/ASX 200 Index at market open today. This inclusion brings the stock into Australia’s main benchmark index, which is tracked by institutional and passive funds. Being part of the index can lead to increased demand as index funds adjust their holdings. It also enhances visibility among larger investors and may improve liquidity over time.
Key Takeaways
- 4DMedical Ltd has seen a remarkable rise in value, with a 2,000% increase over the past year.
- The company has secured key partnerships and regulatory approvals, enhancing its market position.
- Reimbursement codes in the U.S. offer a clear revenue pathway for its technologies.
- Inclusion in the ASX 200 Index increases visibility and potential for growth.
As the company continues to expand its footprint in the healthcare sector, investors are watching closely to see how these developments translate into long-term value.
